Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1 Recurrence 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ovarian Cancer Recurrent 1 Neoplasm Metastasis 1 Hematologic Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Gemcitabine 97 130-nm albumin-bound paclitaxel 47 Albumin-Bound Paclitaxel 36 Oxaliplatin 27 Fluorouracil 26 Capecitabine 20 Taxes 19 Leucovorin 19 pembrolizumab 18 Cyclophosphamide 18 Irinotecan 16 Bevacizumab 12 fludarabine 11 Nivolumab 11 Cetuximab 11 Cisplatin 10 durvalumab 8 Radiotherapy 8 spartalizumab 7 aldesleukin 7 Erlotinib Hydrochloride 7 Drug Therapy 7 avelumab 6 Radiosurgery 6 Paclitaxel 6 irinotecan sucrosofate 5 folfirinox 5 Ipilimumab 5 Injections 5 ALT-803 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Neoplasms × poly(I).poly(c12,U) × Clear all

NCT05927142 2025-02-25

DURIPANC

Erasmus Medical Center

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡